Literature DB >> 10882700

Resistance of helicobacter pylori to metronidazole, tetracycline and amoxycillin.

H Wu1, X D Shi, H T Wang, J X Liu.   

Abstract

Resistance to metronidazole, tetracycline and amoxycillin, and beta-lactamase production were determined for 153 clinical isolates of Helicobacter pylori. Of these isolates, 77.8% were resistant to metronidazole (MIC > 8 mg/L), 58.8% to tetracycline (MIC > 16 mg/L) and 71.9% to amoxycillin (MIC > 0.5 mg/L); 39.2% were multiresistant. Resistance to metronidazole was more common in isolates from females than in those from males (P < 0.05). None of the isolates produced beta-lactamase, so the mechanism of amoxycillin resistance was not linked to production of beta-lactamase.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882700     DOI: 10.1093/jac/46.1.121

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  25 in total

1.  Susceptibilities to different antibiotics of Helicobacter pylori strains isolated from patients at the pediatric medical center of Tehran, Iran.

Authors:  Tahereh Falsafi; Fatemeh Mobasheri; Farahnaz Nariman; Mehri Najafi
Journal:  J Clin Microbiol       Date:  2004-01       Impact factor: 5.948

Review 2.  H pylori antibiotic resistance: prevalence, importance, and advances in testing.

Authors:  F Mégraud
Journal:  Gut       Date:  2004-09       Impact factor: 23.059

3.  Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh.

Authors:  Shamsun Nahar; Asish K Mukhopadhyay; Rasel Khan; Mian Mashhud Ahmad; Simanti Datta; Santanu Chattopadhyay; Swapan Chandra Dhar; Shafiqul Alam Sarker; Lars Engstrand; Douglas E Berg; G Balakrish Nair; Motiur Rahman
Journal:  J Clin Microbiol       Date:  2004-10       Impact factor: 5.948

4.  In vitro and in vivo investigation of drug-eluting implants for the treatment of periodontal disease.

Authors:  Fu-Ying Lee; Dave W Chen; Chih-Chien Hu; Yu-Te Hsieh; Shih-Jung Liu; Err-Cheng Chan
Journal:  AAPS PharmSciTech       Date:  2011-08-31       Impact factor: 3.246

5.  Preclinical experiments on the release behavior of biodegradable nanofibrous multipharmaceutical membranes in a model of four-wall intrabony defect.

Authors:  Dave Wei-Chih Chen; Fu-Ying Lee; Jun-Yi Liao; Shih-Jung Liu; Chao-Ying Hsiao; Jan-Kan Chen
Journal:  Antimicrob Agents Chemother       Date:  2012-09-04       Impact factor: 5.191

6.  Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.

Authors:  Seyed Amir Mirbagheri; Mehrdad Hasibi; Mehdi Abouzari; Armin Rashidi
Journal:  World J Gastroenterol       Date:  2006-08-14       Impact factor: 5.742

7.  Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.

Authors:  Guofei Dai; Ni Cheng; Lei Dong; Mutsumi Muramatsu; Shudong Xiao; Ming-Wei Wang; De-Xu Zhu
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Mutations in the 16S rRNA genes of Helicobacter pylori mediate resistance to tetracycline.

Authors:  Catharine A Trieber; Diane E Taylor
Journal:  J Bacteriol       Date:  2002-04       Impact factor: 3.490

9.  Who's Winning the War? Molecular Mechanisms of Antibiotic Resistance in Helicobacter pylori.

Authors:  Kathleen R Jones; Jeong-Heon Cha; D Scott Merrell
Journal:  Curr Drug ther       Date:  2008-09-01

10.  Effects of 16S rRNA gene mutations on tetracycline resistance in Helicobacter pylori.

Authors:  Monique M Gerrits; Marco Berning; Arnoud H M Van Vliet; Ernst J Kuipers; Johannes G Kusters
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.